Precision Medicine
Treatment decisions grounded in the patient’s own tumour.
Ex-vivo tumour models and functional drug sensitivity testing, combined with genomic profiling and multidisciplinary review, used to narrow down which regimens are likely to work for an individual patient.
What is included
- Patient-derived tumour models: PDC, PDO, PDX and humanised immune models
- Functional drug sensitivity testing rather than genomic prediction alone
- MDT review that re-reads pathology slides and imaging together
- Case banking for patients whose tumour evolves over time
Who it is forPatients with a confirmed diagnosis who have progressed on, or are deciding between, systemic regimens.
